ABT241108P115000
- 0.41
- -0.05-10.87%
Abbott Laboratories Newsroom
Abbott Laboratories Analyst Ratings
Barclays Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $149
Barclays Maintains Abbott Laboratories(ABT.US) With Buy Rating, Raises Target Price to $149
Barclays Adjusts Abbott Laboratories Price Target to $149 From $143
Oppenheimer Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $130
Piper Sandler Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $133
BofA Securities Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $133
Wells Fargo Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $133
TD Cowen Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $130
Argus Adjusts Price Target on Abbott Laboratories to $145 From $135
A Quick Look at Today's Ratings for Abbott Laboratories(ABT.US), With a Forecast Between $130 to $146
Abbott Labs Is Maintained at Neutral by Mizuho
Abbott Labs Price Target Raised to $130.00/Share From $115.00 by Mizuho
A Quick Look at Today's Ratings for Abbott Laboratories(ABT.US), With a Forecast Between $125 to $146
Abbott Laboratories Analyst Ratings
Goldman Sachs Remains a Buy on Abbott Laboratories (ABT)
Abbott Laboratories (ABT) Gets a Buy From Piper Sandler
Analysts Offer Insights on Healthcare Companies: Resmed (RMD) and Abbott Laboratories (ABT)
Travis Steed Reiterates Buy Rating on Abbott Laboratories Amid Promising Growth and Under-Ownership Potential
Abbott Laboratories: Buy Rating Reaffirmed Amid Strong Medical Device Performance and Positive Long-Term Growth Outlook